TY - JOUR T1 - Recommendations of the Spanish Society of Rheumatology on Treatment and Use of Systemic Biological and Non-biological Therapies in Psoriatic Arthritis JO - Reumatología Clínica (English Edition) T2 - AU - Torre Alonso,Juan Carlos AU - Díaz del Campo Fontecha,Petra AU - Almodóvar,Raquel AU - Cañete,Juan D. AU - Montilla Morales,Carlos AU - Moreno,Mireia AU - Plasencia-Rodríguez,Chamaida AU - Ramírez García,Julio AU - Queiro,Rubén SN - 21735743 M3 - 10.1016/j.reumae.2017.08.002 DO - 10.1016/j.reumae.2017.08.002 UR - https://reumatologiaclinica.org/en-recommendations-spanish-society-rheumatology-on-articulo-S2173574318300790 AB - ObjectiveThe main purpose of this recommendation statement is to provide clinicians with the best available evidence and the best opinion agreed upon by the panellists for a rational use of synthetic disease modifying antirheumatic drugs (DMARDs) and biologicals in psoriatic arthritis (PsA) patients. The present document also focuses on important aspects in the management of PsA, such as early diagnosis, therapeutic objectives, comorbidities and optimisation of treatment. MethodsThe recommendations were agreed by consensus by a panel of 8 expert rheumatologists, previously selected by the Spanish Society of Rheumatology (SER) through an open call. The phases of the work were: identification of key areas for updating the previous consensus, analysis and synthesis of scientific evidence (modified Oxford system, Centre for Evidence-based Medicine, 2009) and formulation of recommendations based on this evidence and by consensus techniques. ResultsSeventeen recommendations were issued for the treatment of PsA patients. Six of them were of general nature, ranging from the early diagnosis and treatment to the importance of assessing comorbidities. The other 11 were focused on the indications for DMARDs and biological therapy in the distinct clinical forms of the disease. Likewise, the situation of failure of the first biological is addressed and treatment algorithms and a table with the different biological therapies are also included. ConclusionsWe present the update of SER recommendations for the treatment of PsA with DMARDs and biologics. ER -